Clay Siegall, CEO and Co-Founder at Seattle Genetics

Dr. Siegall is a co-founder at Seattle Genetics where he serves as the chair, president, and chief executive officer. Siegall became interested in oncology when his father was first diagnosed with brain cancer. As a result, Siegall pursued zoology. Later in his career, he became the first Chief Executive Officer at Seattle Genetics Inc. in 2002. For over 20 years, Dr. Siegall has been actively involved in therapeutic drug development.

Through his official blog page, Dr. Siegall recently covered Trumps’ visit to Texas, solely to inspect the extent of damages caused by the storm. Dr. Clay Siegall noted that President Trump is among several other Americans are overly committed to making sure safety of those affected by the hurricane. With commitment, President Trump signed a disaster declaration on Friday night, for Texas. On Monday, Trump also signed another emergence declaration for Louisiana.

In another similar post, Dr. Siegall shared Staley’s knee injury desperation for the Sunday preseason. He, however, shared the hope that Staley’s injury will have recovered by week one even with the knee tendonitis. According to Shanahan, Joe Staley caught a turf spike by tweaking the knee on the first possession of the game.

Through Dr. Siegall’s exemplary leadership skills, Seattle Genetics has managed to come up with a range of cancer therapies that are antibody-based. Similarly, the company came up with ADCETRIS; this drug was promptly approved by the United States Food and Drug Administration in 2011. Dr. Siegall studied in Maryland University where he earned a B.S degree in Zoology. He also pursued his Ph.D. in Genetics at George Washington University.

Further, Dr. Siegall has been resourceful in various capital raising activities at Seattle Genetics. His active involvement enabled Seattle Genetics to secure over $675 million from both private and public financings. Dr. Siegall formerly worked with Bristol-Myers Squibb Pharmaceutical Research Institute until 1997. Apparently, Dr. Siegall works at a board of directors at a biotechnology company, Alder BioPharmaceuticals. For the record, Dr. Siegall holds 15 patents and over 70 publications. Dr. Siegall is highly experienced in biotechnology and holds a good record of managerial competence.